We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.6B
AUM Growth
+$151M
Cap. Flow
-$15.9M
Cap. Flow %
-0.61%
Top 10 Hldgs %
41.87%
Holding
167
New
13
Increased
21
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$23.6M
3
VTRS icon
Viatris
VTRS
+$18.4M
4
ABT icon
Abbott
ABT
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.7M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$20.5M
2
HCA icon
HCA Healthcare
HCA
+$18.3M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.9M
4
MDVN
MEDIVATION, INC.
MDVN
+$15.5M
5
STJ
St Jude Medical
STJ
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Real Estate 2.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
101
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.88M 0.11%
125,000
– –
FWP
102
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.87M 0.11%
19,507
– –
DERM
103
DELISTED
Dermira, Inc.
DERM
$2.79M 0.11%
+82,600
New +$2.66M
GRFS
104
Grifois
GRFS
$5.58B
$2.65M 0.1%
166,000
– –
NVRO
105
DELISTED
NEVRO CORP.
NVRO
$2.61M 0.1%
25,000
-24,800
-50% -$2.24M
MCK icon
106
McKesson
MCK
$101B
$2.5M 0.1%
15,000
– –
DPLO
107
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$2.44M 0.09%
+87,163
New +$2.92M
HALO icon
108
Halozyme
HALO
$9.88B
$2.42M 0.09%
200,000
– –
DBVT
109
DBV Technologies
DBVT
$817M
$2.38M 0.09%
6,560
– –
ORKA
110
Oruka Therapeutics
ORKA
$5.9B
$2.34M 0.09%
3,756
– –
MDRX
111
DELISTED
Veradigm Inc. Common Stock
MDRX
$2.29M 0.09%
173,600
– –
TXMD icon
112
TherapeuticsMD
TXMD
$23.5M
$2.09M 0.08%
+6,140
New +$2.24M
DCOY
113
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
FOLD
114
DELISTED
Amicus Therapeutics
FOLD
$1.91M 0.07%
258,000
– –
QURE icon
115
uniQure
QURE
$2.93B
$1.84M 0.07%
241,021
– –
MACK
116
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.82M 0.07%
36,351
– –
MNTA
117
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.8M 0.07%
153,700
– –
ACHC icon
118
Acadia Healthcare
ACHC
$2.62B
$1.74M 0.07%
+35,200
New +$1.83M
RCKT icon
119
Rocket Pharmaceuticals
RCKT
$351M
$1.71M 0.07%
45,191
– –
CMRX
120
DELISTED
Chimerix, Inc.
CMRX
$1.71M 0.07%
308,892
– –
CDTX
121
DELISTED
Cidara Therapeutics
CDTX
$1.52M 0.06%
6,624
– –
ESPR
122
DELISTED
Esperion Therapeutics
ESPR
$1.42M 0.05%
102,800
– –
CYTO
123
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.34M 0.05%
10
– –
ADYX
124
DELISTED
Adynxx Inc
ADYX
$1.29M 0.05%
27,500
– –
NTLA icon
125
Intellia Therapeutics
NTLA
$1.55B
$1.22M 0.05%
71,842
-15,000
-17% -$290K
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Tekla Capital Management held 167 positions worth $2.6B, up 6.1% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2016 filing shows 13 new, 21 increased, 24 reduced and 25 closed positions. Its largest new stake was Cardinal Health: 152,500 shares worth $11.8M. The largest sale was Illumina, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2016 buy was Cardinal Health: 152,500 shares worth $11.8M.
  • Tekla Capital Management added most to Merck in Q3 2016, an estimated $27.5M increase.
  • Tekla Capital Management's biggest Q3 2016 reduction was Illumina, cutting an estimated $20.5M.
  • Tekla Capital Management fully exited State Street SPDR S&P Biotech ETF in Q3 2016, selling an estimated $15.9M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.6B portfolio in Q3 2016.
  • Tekla Capital Management opened 13 new positions and closed 25 in Q3 2016.
  • Tekla Capital Management's portfolio value rose 6.1% quarter-over-quarter to $2.6B.

Based on Tekla Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.